Avience Biomedicals IPO: Should You Apply, Avoid, or Wait for the Listing Dip?

Key Takeaways

• Avience Biomedicals IPO on NSE SME is priced at ₹196-₹208 per share, with a total issue size up to ₹30 crore (fresh issue up to ₹29 crore) and 14,53,800 shares on offer; lot size is 600 shares.
• GMP data is not available yet; the most meaningful signal will come from subscription demand and eventual listing performance.
• Key risk: limited company background, SME-status, no confirmed lead manager, and no GMP signal as of now.
• Watchlist – wait for more data post-open (GMP, demand, and listing behavior) before committing capital.

Avience Biomedicals IPO details: price band, lot size, open/close dates, listing date

GMP signals and subscription trend for Avience Biomedicals IPO

As of now, GMP data for Avience Biomedicals IPO is not available, so there is no pre-listing price signal. The subscription trend will be the next big data point, given the small size of the offer and the NSE SME listing. Retail investors should monitor demand across quotas once the book is open and after it closes on 22 June.

Should you apply for Avience Biomedicals IPO at ₹196-₹208?

The price band sits at ₹196-₹208 with 600-share lots and a small ₹30 crore total size, which can be attractive only if the business is clearly visible and the demand supports it. In absence of strong business fundamentals and confirmed GMP, this issue may be suited to investors with high risk tolerance and small-ticket exposure. Evaluate your own risk profile and post-listing plan before applying.

Avience Biomedicals IPO valuation: is ₹196-₹208 justified?

There is no revenue or profit data in the available material, making it difficult to judge valuation against earnings, peers, or growth. The SME context, lack of GMP data, and the small issue size argue for caution. A clean, data-driven decision would require more information after listing or a robust pre-IPO financial track record.

Company background and risk factors for Avience Biomedicals IPO

The source identifies Avience Biomedicals as an SME-IPO issuing 14,53,800 equity shares of ₹10 face value aggregating up to ₹30 crore, with a fresh issue of ₹29 crore. No promoter names, product lines, or detailed business segments are provided in the material. This thin information base heightens execution risk for a small-cap IPO and warrants a cautious approach for retail investors with limited risk capital.

How to apply for Avience Biomedicals IPO: UPI/ASBA steps

Applications can be submitted via ASBA through your bank or via UPI-enabled IPO platforms. Steps include selecting the Avience Biomedicals IPO in your banking app or IPO app, choosing the bid quantity (a multiple of 600 shares), entering your bid price in a bookbuilding issue, and authorizing the bid by confirming your UPI ID. After you submit, funds stay in your account until successful allotment; unused funds are refunded after allotment. For retail investors, platforms like Swastika offer one-click IPO applications, but ensure you understand the risk and the time limits before applying.

Allotment and listing timeline for Avience Biomedicals IPO

The issue opens on 18 Jun 2026 and closes on 22 Jun 2026. Allotment dates and the official registrar details are yet to be announced. The listing is scheduled for 25 Jun 2026 on the NSE SME exchange. Investors should stay alert for the final allotment and listing confirmations from the registrar or exchange.

FAQ

Is Avience Biomedicals IPO worth applying for at ₹196-₹208?

As of now, GMP data is not available and the SME has limited business visibility; decide based on your risk tolerance and post-listing plan.

What is the GMP signal for Avience Biomedicals IPO?

GMP data is not available yet, so there is no pre-listing price signal at this time.

What are the allotment odds for Avience Biomedicals IPO?

Retail quota is 4,81,200 shares with a 600-share lot; allotment depends on demand across all quotas; specific odds are not disclosed.

When is the listing date for Avience Biomedicals IPO?

Listing on NSE SME is expected on 25 Jun 2026.

Who is the IPO registrar and lead manager?

Registrar is Skyline Financial Services Pvt. Ltd; Lead Manager is To be announced.

Conclusion

Avience Biomedicals is a small-ticket SME issue with limited business visibility and no GMP signal yet. Investors should watchlist this IPO for now, because GMP data is unavailable and the business narrative remains thin.

End of note: Watchlist because GMP is not available and data remains thin, so you should wait for more information before committing new capital.

Open your trading and demat account here

‍